Zacks Investment Research
04 Dec 2025, 19:11 UTC · 41w ago
Verdict
Headline leans bullish. We score PHVS +1.00.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
Which stocks this story touches
More positive than 98% of ticker scores this week
Shares rose nearly 22% following positive results from the phase III RAPIDe-3 study for its lead drug.
More negative than 75% of ticker scores this week
Investors are highlighting the potential superiority of a competitor's drug over KalVista's Ekterly.
Continue reading
5 related stories
More positive than 98% of ticker scores this week
Scored by the NIS engine · methodology.
More positive than 78% of relationship scores this week
[mutual] Both companies provide oral on-demand therapies for hereditary angioedema (HAE), with Pharvaris's drug compared directly to KalVista's Ekterly.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+22.6%
Price agrees with the score
$36.02 vs $29.37 close before publication (Dec 3) · not market-adjusted
PHVS chart →